Getting Started With ZEPOSIA
ZEPOSIA is the First and Only S1P With No First-Dose Observation Required1-3
NO First-Dose Observation Required
NO Genetic Testing Required
NO Ophthalmic Testing Required for Most Patients4a
Obtain a recent CBC (within 6 months) or after discontinuation of prior MS therapy
Obtain an ECG to determine whether preexisting conduction abnormalities are present
Obtain transaminase and total bilirubin level (within 6 months)
Evaluate current and prior medications
Patients without a confirmed history of VZV or without documented VZV vaccination should be tested for antibodies. If VZV or other live attenuated immunizations are required, administer at least 1 month prior to initiation
An Up-Titration Schedule Should Be Used to Reach the Maintenance Dose, as a Transient Decrease in Heart Rate and AV Conduction Delays May Occur1
The Mean (CV%) Plasma Half-Life (t1/2) of ZEPOSIA Was Approximately 21 Hours (15%). The Mean Half Life of the Active Metabolite CC112273 Was 11 Days1
Heart Rate Data for Day 1 Initiation Dose (0.25 mg)5-7
aDiabetes mellitus and uveitis increase the risk of macular edema; patients with a history of these conditions should have an ophthalmic evaluation of the fundus, including the macula, prior to treatment initiation. A prompt ophthalmic evaluation is recommended if there is any change in vision while taking ZEPOSIA.1
CBC=complete blood count; ECG=electrocardiography; VZV=varicella-zoster virus.
This information is intended for U.S. Healthcare Professionals.